CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
I'm PortAI, I can summarize articles.
CASI Pharmaceuticals reported a 60% year-over-year drop in Q3 revenue, primarily due to estimated goods returns for EVOMELA, leading to a widened net loss of $10.9 million. The company is appealing Nasdaq's delisting determination and plans to divest its China business by Q2 2026. CASI will present CID-103 study results at ASH 2025 and is advancing trials in the U.S. and China. Wall Street's median 12-month price target for CASI is $4.00, significantly above its current price.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments